Product Name |
Dalbavancin-d6 |
Alternate Names |
Dalbavancin Stable Isotopes, Stable Isotopes of Dalbavancin |
CAT No. |
CS-T-73435
|
CAS No. |
1126461-54-8 |
Category |
Stable Isotopes |
Stock |
IN-Stock
|
Mol. Wt. |
1822.73 g/mol |
Mol. For. |
C₈₈H₉₄D₆Cl₂N₁₀O₂₈
|
Hazardous |
This is a Hazardous Compound
|
COA |
View Sample COA
|
MSDS |
View Sample MSDS
|
Parent API |
Dalbavancin |
Controlled |
No |
Shipping |
Free for purchase above 1000$ |
Delivery |
In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
Return |
Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
Ordering |
Place your order online or by email sales@clearsynth.com |
If you find a better price anywhere else we guarantee Price match.
Dalbavancin-d6 is a deuterated derivative of Dalbavancin, a lipoglycopeptide antibiotic used to treat skin and soft tissue infections caused by Gram-positive bacteria. The deuterated compound is used in pharmacokinetic and pharmacodynamic studies to understand the drug's metabolic pathways and its interactions with other medications.
Dalbavancin-d6 is administered intravenously, and its effects are long-lasting due to its extended half-life of approximately 200 hours. The drug works by inhibiting bacterial cell wall synthesis, leading to bacterial death. It is highly effective against strains of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA).
In terms of chemical information, Dalbavancin-d6 is a lipoglycopeptide consisting of two distinct peptide units with a lipid side chain attached to the N-terminus. The deuterium substitution in the compound does not affect its mechanism of action or pharmacokinetics.
Dalbavancin-d6 should only be used under the guidance of a healthcare professional due to its potential side effects, including nausea, diarrhea, headache, and allergic reactions. It is important to note that the use of antibiotics, including Dalbavancin-d6, can lead to the development of antibiotic resistance if not used appropriately.